Equities

Revolution Medicines Inc

Revolution Medicines Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)60.44
  • Today's Change1.34 / 2.27%
  • Shares traded1.81m
  • 1 Year change+185.36%
  • Beta1.4178
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy8
Outperform7
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 14 analysts offering 12 month price targets for Revolution Medicines Inc have a median target of 70.00, with a high estimate of 86.00 and a low estimate of 63.00. The median estimate represents a 15.82% increase from the last price of 60.44.
High42.3%86.00
Med15.8%70.00
Low4.2%63.00

Earnings history & estimates in USD

On Nov 06, 2024, Revolution Medicines Inc reported 3rd quarter 2024 losses of -0.94 per share.
The next earnings announcement is expected on Feb 24, 2025.
Average growth rate-1.99%
Revolution Medicines Inc reported annual 2023 losses of -3.86 per share on Feb 26, 2024.
Average growth rate+4.49%
More ▼

Revenue history & estimates in USD

Revolution Medicines, Inc. did not report revenues for the 3rd quarter 2024. However, during the 3rd quarter of the prior year the company reported revenues of 7.01m.
Average growth rate-33.33%
Revolution Medicines, Inc. had revenues for the full year 2023 of 11.58m. This was 67.27% below the prior year's results.
Average growth rate-23.15%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.